Tryptophan metabolism in tumor microenvironment and therapeutic implications

Area of Science:

• Oncology
• Immunology
• Metabolism

Background:

• Tryptophan (Trp) catabolism is a known immunosuppressive mechanism in cancer, primarily attributed to indoleamine-2,3-dioxygenase 1 (IDO1).
• The clinical inefficacy of IDO1 inhibitors highlights the need for a broader understanding beyond this single enzyme.

Purpose of the Study:

• To consolidate current knowledge on Trp metabolism in cancer.
• To propose novel biomarker-guided, multi-node intervention strategies for precision immuno-oncology.
• To re-establish Trp metabolism as a viable target in cancer immunotherapy.

Main Methods:

• Comprehensive review of Trp metabolic pathways and key enzymes.
• Synthesis of Trp metabolites' immunomodulatory effects on T cells in the tumor microenvironment.
• Analysis of tumor cell manipulation of Trp metabolism for survival and metastasis.
• Proposal of a new therapeutic framework combining enzyme inhibitors or Aryl hydrocarbon receptor (AhR) antagonists with immune checkpoint blockade.

Main Results:

• Detailed description of Trp metabolic pathways and enzymes as potential therapeutic targets.
• Elucidation of how Trp metabolites influence immune surveillance and immunotherapy efficacy.
• Understanding of tumor-driven Trp metabolic reprogramming.
• A novel framework for targeting Trp metabolism beyond IDO1.

Conclusions:

• Shifting from an IDO1-centric view to comprehensive metabolic interventions can unlock Trp metabolism's potential in cancer immunotherapy.
• Targeting multiple nodes within Trp metabolism, potentially combined with immune checkpoint blockade, represents a promising precision immuno-oncology approach.